- Home
- CLSD vs IMMX Comparison
CLSD vs IMMX Comparison
Compare CLSD & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- IMMX
- Stock Information
- Founded
- CLSD 2011
- IMMX 2014
- Country
- CLSD United States
- IMMX United States
- Employees
- CLSD N/A
- IMMX N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CLSD Health Care
- IMMX Health Care
- Exchange
- CLSD Nasdaq
- IMMX Nasdaq
- Market Cap
- CLSD 68.4M
- IMMX 65.5M
- IPO Year
- CLSD 2016
- IMMX 2021
- Fundamental
- Price
- CLSD $4.37
- IMMX $2.06
- Analyst Decision
- CLSD Hold
- IMMX Strong Buy
- Analyst Count
- CLSD 4
- IMMX 1
- Target Price
- CLSD $65.00
- IMMX $8.00
- AVG Volume (30 Days)
- CLSD 78.5K
- IMMX 172.6K
- Earning Date
- CLSD 11-11-2025
- IMMX 11-11-2025
- Dividend Yield
- CLSD N/A
- IMMX N/A
- EPS Growth
- CLSD N/A
- IMMX N/A
- EPS
- CLSD N/A
- IMMX N/A
- Revenue
- CLSD $4,166,000.00
- IMMX N/A
- Revenue This Year
- CLSD $98.20
- IMMX N/A
- Revenue Next Year
- CLSD $213.77
- IMMX N/A
- P/E Ratio
- CLSD N/A
- IMMX N/A
- Revenue Growth
- CLSD N/A
- IMMX N/A
- 52 Week Low
- CLSD $3.32
- IMMX $1.26
- 52 Week High
- CLSD $24.75
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- CLSD 45.81
- IMMX 44.33
- Support Level
- CLSD $4.00
- IMMX $1.98
- Resistance Level
- CLSD $4.45
- IMMX $2.15
- Average True Range (ATR)
- CLSD 0.40
- IMMX 0.13
- MACD
- CLSD 0.13
- IMMX 0.01
- Stochastic Oscillator
- CLSD 83.87
- IMMX 34.29
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.